Background: Inhaled nitric oxide produces potent pulmonary vasodilation by activating soluble guanylate cyclase and increasing smooth muscle cell concentrations of cyclic guanosine monophosphate. However, responses are often nonsustained, and clinically significant increases in pulmonary vascular resistance have been noted on its acute withdrawal. In vitro and in vivo data suggest that inhaled nitric oxide decreases endogenous nitric oxide synthase activity. The effects of inhaled nitric oxide on the downstream mediators of the nitric oxide/cyclic guanosine monophosphate cascade, soluble guanylate cyclase and phosphodiesterase 5, have not been investigated. We sought to determine the effects of inhaled nitric oxide on endogenous cyclic guanosine monophosphate levels, soluble guanylate cyclase, and phosphodiesterase 5 protein levels in the intact lamb.
Methods: Eleven 1-month-old lambs were mechanically ventilated. In 7 lambs, inhaled nitric oxide (40 ppm) was administered for 24 hours and then acutely withdrawn. Intermittent lung biopsy samples were obtained for cyclic guanosine monophosphate concentrations and soluble guanylate cyclase and phosphodiesterase 5 protein levels (Western blot analysis).
Results: Initiation of nitric oxide decreased left pulmonary vascular resistance by 26.2%, and withdrawal rapidly increased pulmonary vascular resistance by 77.8% (P Ͻ .05). Tissue cyclic guanosine monophosphate concentrations initially increased during nitric oxide therapy but were not maintained during the 24-hour exposure. In addition, cyclic guanosine monophosphate concentrations rapidly decreased after nitric oxide withdrawal (P Ͻ .05). The ␣ soluble guanylate cyclase (Ϫ45.7%) and ␤ soluble guanylate cyclase (Ϫ48.4%) protein levels decreased during nitric oxide therapy (P Ͻ .05), whereas phosphodiesterase 5 proteins levels were unchanged.
Conclusions:
These data suggest a role for decreased soluble guanylate cyclase and its resulting decrease in cyclic guanosine monophosphate concentrations in the nonsustained response to nitric oxide and the rebound pulmonary hypertension noted on its acute withdrawal. Phosphodiesterase 5 inhibitors may be a useful adjunct therapy during inhaled nitric oxide to preserve cyclic guanosine monophosphate levels and thereby preserve nitric oxide responsiveness and prevent rebound pulmonary hypertension. E xogenously administered inhaled nitric oxide (NO) is currently used as an adjuvant therapy for a number of pulmonary hypertensive disorders. In both animal and human studies, inhaled NO (5 to 80 ppm) induces rapid and selective pulmonary vasodilation. [1] [2] [3] [4] When administered into the airways in its gaseous form, NO diffuses into pulmonary vascular smooth muscle cells and activates soluble guanylate cyclase (sGC), a heterodimer with ␣ 1 and ␤ 1 subunits that catalyzes the production of cyclic guanosine monophosphate (cGMP) from guanosine-5'-triphosphate. Cyclic GMP induces vascular smooth muscle relaxation through activation of a cGMP-dependent protein kinase, although the exact mechanism remains unclear. 5, 6 Cyclic nucleotide phosphodiesterases (PDEs) regulate intracellular levels of cGMP by catalyzing cGMP to GMP. 7 PDE 5 is the predominant cGMP-metabolizing PDE of pulmonary tissues. 8 Several clinical trials have demonstrated that inhaled NO improves oxygenation and decreases the need for extracorporeal life support in neonates with persistent pulmonary hypertension. 2, 3 In addition, nonrandomized studies demonstrate that inhaled NO selectively decreases pulmonary arterial pressure and pulmonary vascular resistance in patients with perioperative pulmonary hypertension and decreases pulmonary vascular resistance and improves oxygenation in patients with acute lung injury. 1, 4 Although these data are encouraging, nonsustained responsiveness is common, and concerns regarding the safety of inhaled NO therapy remain. For example, in acute lung injury, inhaled NO improves oxygenation on initiation, but this effect is not sustained. 9, 10 In addition, several studies have noted a potentially life-threatening increase in pulmonary vascular resistance on acute withdrawal of inhaled NO. 11, 12 This rebound pulmonary hypertension is manifested by an increase in pulmonary vascular resistance, compromised cardiac output, severe hypoxemia, or a combination of these. 11, 12 Increasing data demonstrate that exogenous NO exposure inhibits endogenous endothelial NO synthase (NOS) activity, suggesting that transient decreases in endogenous NOS activity during inhaled NO therapy may be a potential mechanism for rebound pulmonary hypertension. [13] [14] [15] Limited in vitro data suggest that exogenous NO may directly alter sGC gene expression. 16, 17 However, the potential effects of inhaled NO on pulmonary sGC and PDE 5 signaling in vivo are unknown.
The purpose of this study was to investigate the effects of inhaled NO endogenous sGC and PDE 5 protein levels in the intact lamb. To this end, inhaled NO (40 ppm) was administered to 7 intact 1-month-old lambs for 24 hours and then acutely withdrawn. Sequential blood was taken for plasma cGMP determinations, and sequential peripheral lung biopsy samples were taken for tissue cGMP determinations and protein level determinations of sGC and PDE 5 by Western blot analysis. Four additional lambs underwent an identical protocol without inhaled NO therapy.
Methods

Surgical Preparation
Eleven lambs (30.1 Ϯ 4.3 days old) were fasted for 24 hours, with free access to water. The lambs were then anesthetized with ketamine hydrochloride (15 mg/kg intramuscularly). With lambs under additional local anesthesia with 1% lidocaine hydrochloride, polyurethane catheters were placed in an artery and vein of a hind leg. These catheters were advanced to the descending aorta and the inferior vena cava, respectively. The lambs were then anesthetized with ketamine hydrochloride (approximately 0.3 mg · kg Ϫ1 · min Ϫ1 ), diazepam (0.002 mg · kg Ϫ1 · min Ϫ1 ), and fentanyl citrate (1.0 g · kg Ϫ1 · h Ϫ1 ), intubated with a 7.0-mm-outer-diameter cuffed endotracheal tube, and mechanically ventilated with a Healthdyne pediatric time-cycled, pressure-limited ventilator. Pancuronium bromide (0.1 mg/kg per dose) was given intermittently for muscle relaxation. By using strict aseptic technique, a midsternotomy incision was then performed, and the pericardium was incised. By using a purse-string suture technique, polyurethane catheters were placed directly into the right and left atrium and the main pulmonary artery. An ultrasonic flow probe (Transonics Systems, Ithaca, NY) was placed around the left pulmonary artery to measure pulmonary blood flow. The midsternotomy incision was then temporarily closed with towel clamps. An intravenous infusion of Ringer's lactate and 5% dextrose (75 mL/h) was begun and continued throughout the study period. Cefazolin (500 mg IV) and gentamicin (3 mg/kg IV) were administered before the first surgical incision and every 8 hours thereafter. The lambs were maintained normothermic (39°C) with a heating blanket.
Experimental Protocol
After a 30-minute recovery, baseline measurements of the hemodynamic variables (pulmonary and systemic arterial pressure, heart rate, left pulmonary blood flow, and left and right atrial pressures), systemic arterial blood gases, and pH were measured (before NO). Blood was obtained for plasma cGMP determinations, and peripheral lung wedge biopsy samples were obtained for tissue cGMP determinations and sGC and PDE 5 protein determinations. A side-biting vascular clamp was used to isolate peripheral lung tissue from a randomly selected lobe, and the incision was cauterized. Approximately 300 mg of peripheral lung was obtained for each biopsy sample.
In 7 of the lambs, inhaled NO (40 ppm) was then delivered in nitrogen into the inspiratory limb of the ventilator (Inovent; Ohmeda Inc, Liberty, NJ) and continued for 24 hours. The inspired concentrations of NO and nitrogen dioxide were continuously quantified by electrochemical methodology (Inovent). The hemodynamic variables were monitored continuously. Systemic arterial blood gases were determined intermittently, and ventilation was adjusted to achieve a PaCO 2 between 32 and 45 mm Hg and a PaO 2 greater than 50 mm Hg. Sodium bicarbonate was administered intermittently to maintain a pH greater than 7.30. Normal saline was administered intermittently to maintain stable atrial pressures throughout the study period. Peripheral lung wedge biopsies were performed after 2, 6, and 24 hours of therapy. The inhaled NO was then stopped, and the hemodynamic variables were monitored for 2 additional hours. To ensure that the potential changes demonstrated resulted from inhaled NO and not from mechanical ventilation alone, 4 lambs were mechanically ventilated for 24 hours, as described previously, without inhaled NO therapy.
At the end of the protocol, all lambs were killed with a lethal injection of sodium pentobarbital followed by bilateral thoracotomy as described in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All protocols and procedures were approved by the Committee on Animal Research of the University of California, San Francisco. All animals received humane care in compliance with the Guide for the Care and Use of Laboratory Animals.
Measurements
Pulmonary and systemic arterial and right and left atrial pressures were measured with Sorenson Neonatal Transducers (Abbott Critical Care Systems, North Chicago, Ill). Mean pressures were obtained by electrical integration. Heart rate was measured by a cardiotachometer triggered from the phasic systemic arterial pressure pulse wave. Left pulmonary blood flow was measured on an ultrasonic flow meter (Transonic Systems). All hemodynamic variables were recorded continuously on a Gould multichannel electrostatic recorder (Gould Inc, Cleveland, Ohio). Systemic arterial blood gases and pH were measured on a Radiometer ABL5 pH/ blood gas analyzer (Radiometer, Copenhagen, Denmark). Hemoglobin concentration and oxygen saturation were measured by a hemoximeter (model 270, Ciba-Corning, East Walpole, Mass). Pulmonary vascular resistance was calculated by using standard formulas. Body temperature was monitored continuously with a rectal temperature probe.
Cyclic GMP Determinations
Blood samples (1-2 mL) were collected in iced Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ) containing ethylenediaminetetraacetic acid (7.5 mmol/L). The samples were centrifuged (4000g for 15 minutes), and the resulting plasma was stored in polypropylene storage tubes at Ϫ70°C. At the time of the assay, the plasma (200 L) was diluted 1:1 with 0.2 mol/L HCL and vortexed, and the acidified plasma was passed through a 0.2-m Centrex filter (Schleicher & Schuell Inc, Keene, NH) by centrifugation (4000g for 15 minutes). Tissue was homogenized in 6% trichloroacetic acid at 4°C to give a 10% wt/vol homogenate and centrifuged at 2000 revolutions per minute for 15 minutes at 4°C. The supernatant was recovered and washed 4 times with 5 volumes of water-saturated diethyl ether. Aqueous extracts were then lyophilized, and the dried pellet was resuspended in assay buffer before analysis. The samples were assayed with a cGMP (iodine 125) radioimmunoassay kit (Amersham International, Amersham, UK) according to the manufacturer's instructions. Cross-reactivity for other nucleotides was less than 0.001.
Western Blot Analysis
Western blot analysis was performed as previously described. 18 Protein extracts prepared from lung biopsy samples (100 g) were separated on 10% sodium dodecyl sulfate-polyacrylamide gel and electrophoretically transferred to Hybond polyvinylidene difluoride membranes (Amersham, Arlington Heights, IL). The membranes were blocked with 5% nonfat dry milk in Tris-buffered saline containing 0.1% Tween. After blocking, the membranes were incubated at room temperature with the appropriate dilution of the antiserum of interest (1:1000 for the ␣ 1 subunit of guanylate cyclase, 1:10,000 for the 
Statistical Analysis
The mean Ϯ SE was calculated for the baseline hemodynamic variables, systemic arterial blood gases, pH, and cGMP concentrations. Comparisons over time were made by analysis of variance for repeated measures. The mean Ϯ SE was calculated for the relative protein of interest from pre-and post-NO lungs. Results from pre-NO lungs were assigned the value of 1 (relative protein of interest). Comparisons were made by the paired t test.
Results
Inhaled NO (40 ppm) transiently decreased mean pulmonary arterial pressure and left pulmonary vascular resistance (from to 0.242 Ϯ 0.04 to 0.179 Ϯ 0.02 mm Hg/mL per minute per kilogram; P Ͻ .05; Table 1, Figure 1 ). Left pulmonary blood flow, mean systemic arterial pressure, heart rate, right and left atrial pressures, systemic arterial blood gases, and pH were all unchanged. During the 24-hour treatment course, pulmonary arterial pressure returned to the pre-NO value. Systemic arterial pressure slightly decreased and systemic arterial PCO 2 increased in comparison to pre-NO values (Table 1) . On discontinuation of inhaled NO, there was a rapid increase in both mean pul- monary arterial pressure and left pulmonary vascular resistance (P Ͻ .05; Table 1, Figure 1 ). Right atrial pressure increased, and systemic arterial PO 2 decreased (P Ͻ .05). Left pulmonary blood flow, mean systemic arterial pressure, heart rate, left atrial pressures, systemic arterial PCO 2 , and pH remained unchanged from 24-hour NO values (Table 1) . Ventilation alone, without inhaled NO, did not change mean pulmonary arterial pressure, pulmonary blood flow, pulmonary vascular resistance, left and right atrial pressures, heart rate, systemic arterial blood gases, or pH. Mean systemic arterial pressure decreased slightly from 71.8 Ϯ 11.1 mm Hg to 61.0 Ϯ 7.4 mm Hg (P Ͻ .05).
To determine the effects of inhaled NO on endogenous cGMP production, we determined plasma and lung tissue cGMP concentrations. We found that plasma cGMP concentrations increased on initiation of inhaled NO and remained increased during the 24-hour treatment period (P Ͻ .05). Withdrawal of NO was associated with a decrease in cGMP concentrations, which remained decreased 2 hours after discontinuation (Figure 2) . Similarly, lung tissue concentrations of cGMP increased on initiation of inhaled NO (P Ͻ .05). However, this increase was not sustained during the 24-hour treatment period. Withdrawal of NO was also associated with a rapid decrease in tissue cGMP levels, which remained below baseline values during the 2-hour observation period (P Ͻ .05; Figure 3) .
Inhaled NO therapy decreased protein levels of both the ␣ 1 subunit of sGC and the ␤ 1 subunit of sGC (P Ͻ .05; Figures 4 and 5) . However, ventilation alone, without inhaled NO, did not change protein levels (Figures 4 and 5) . PDE 5 protein levels were not changed during inhaled NO ( Figure 6 ).
Discussion
Although many studies demonstrate a clear benefit in patient outcome with inhaled NO use, several safety concerns remain, including its potential acute and chronic adverse effects on endogenous endothelial function. [1] [2] [3] [4] [9] [10] [11] [12] For example, recent in vitro and in vivo data suggest that exogenous NO decreases endogenous NOS activity. 13, 14 However, the potential effects of inhaled NO on downstream mediators of the NO-cGMP cascade had not been investi- gated. To our knowledge, this study is the first in vivo investigation of the effects of exogenous inhaled NO therapy on endogenous sGC and PDE 5 protein expression. Using a sequential lung biopsy technique in the intact 1-month-old lamb, we found that inhaled NO decreases lung tissue sGC protein levels by approximately 50%, whereas PDE 5 levels are unchanged. These net alterations result in decreased endogenous pulmonary cGMP production during and after inhaled NO withdrawal. Soluble GC is a heterodimeric enzyme composed of 2 subunits, termed ␣ and ␤, that generates cGMP from guanosine 5Ј triphosphate. 19 Although much focus has been placed on potential alterations in NOS expression in pulmonary hypertensive disorders, data also suggest that potential changes in sGC expression and activity may be important in the pathophysiology of pulmonary hypertension. [20] [21] [22] For example, decreased sGC protein levels and activity have been demonstrated in animal models of persistent pulmonary hypertension of the neonate. 21, 22 In vitro, this is associated with impairment in the pulmonary vasodilating response to NO donors and may play a role in the decreased responsiveness of some neonates with persistent pulmonary hypertension of the neonate. 21, 22 Decreases in sGC gene expression and activity have also been implicated in other vascular disorders, including essential hypertension. 23 Although few data are available on the regulation of sGC, limited in vitro studies suggest that exogenous NO does alter sGC expression and activity. For example, in rat medullary interstitial cells, NO-donor compounds decreased the messenger RNA levels of both ␣ 1 and ␤ 1 sGC subunits. 16 In addition, in rat pulmonary artery smooth muscle cells, exposure to NO donors induced a cGMP-dependent decrease in sGC messenger RNA and protein levels. 17 This study is the first in vivo demonstration that inhaled NO decreases pulmonary ␣ 1 and ␤ 1 sGC protein levels. We speculate that this effect is mediated by a direct effect of exogenous NO exposure, as demonstrated in pulmonary vascular smooth muscle cells. 17 However, in the kidney, endogenous NOS inhibition has been demonstrated to decrease sGC activity. 24 Therefore, a potential secondary effect of the decreased endogenous NOS activity, which occurs during NO exposure, on sGC cannot be excluded. 13, 14 These and other potential mechanisms require further study.
Intracellular cGMP concentrations are not determined simply by the accumulation of cGMP, but rather by a balance between synthesis and degradation. Cyclic nucleotide PDEs are the enzymes responsible for cGMP degradation. 7 In the mammalian lung, there are a number of PDEs, but the cGMP-specific PDE, PDE 5, is prevalent, especially early in development. 8 In this study we have demonstrated that the expression of PDE 5 is unchanged during inhaled NO therapy. As with sGC, little is known about the regulation of PDE 5 gene expression. However, developmental regulation and alterations in animal models of pulmonary hypertension have been demonstrated. 8, 25 Previous in vivo and in vitro data demonstrate that inhaled NO decreases endogenous NOS activity via an endothelin-1-dependent process, suggesting that decreased endogenous NOS activity mediates, at least in part, the rebound pulmonary hypertension associated with withdrawal of inhaled NO therapy. 13, 14, 26, 27 In this study, independent of changes in NOS, the net effect of decreased sGC without a compensatory decrease in PDE 5 may result in decreased cGMP production. This may explain why the initial increase in tissue cGMP concentrations during inhaled NO therapy did not persist throughout the entire 24-hour treatment period ( Figure 3) and is a potential etiology for nonsustained NO responses demonstrated in human trials. 9, 10 Similarly, on withdrawal of exogenous NO, basal cGMP production will be decreased and may contrib- 
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Thelitz et al ute to the physiologic increase in pulmonary vascular resistance noted on NO withdrawal. It is interesting to note that changes in plasma cGMP levels did not completely track with lung tissue cGMP levels (Figures 2 and 3) . Similar to tissue levels, plasma levels increased on initiation of inhaled NO. However, unlike tissue levels, plasma cGMP levels remained increased throughout the 24-hour NO therapy and decreased only after NO was discontinued. Cyclic GMP production is the result of 2 major sources: activation of sGC via NO and activation of particulate guanylate cyclase via natriuretic peptides. 28 Plasma cGMP levels reflect pulmonary and systemic vascular NO production, nonvascular NO production, and natriuretic peptide production, of which the myocardium is a major source. Lung tissue cGMP levels predominantly reflect vascular and nonvascular pulmonary NO production. Therefore, changes in tissue cGMP are more likely to reflect changes in endogenous pulmonary NO and subsequent cGMP production, whereas plasma levels are likely to be altered by other compensatory factors, such as changes in natriuretic peptide production. Although potential alterations in natriuretic peptide production and other nonpulmonary sources of cGMP during inhaled NO are unclear, the current data suggest potential changes that warrant further investigation.
Several limitations of this study are noteworthy. First, only 1 dose of inhaled NO (40 ppm) and 1 treatment duration (24 hours) were studied. In addition, rapid withdrawal of a high dose was used, as opposed to the slower weaning strategy that is often used clinically. Further investigations are needed to determine the potential effects of different doses, treatment durations, and weaning strategies on endogenous sGC and PDE 5. Finally, these studies were performed in lambs with normal pulmonary circulations. Patients with pulmonary hypertension, who are currently treated with inhaled NO, often have preexisting aberrations in the NO-cGMP cascades. 20 Further studies are warranted, and ongoing, to determine the effects of inhaled NO in abnormal pulmonary circulation.
This study is the first in vivo investigation of the effects of inhaled NO therapy on endogenous sGC and PDE 5 expression. We found that exogenous inhaled NO induces a significant decrease of sGC protein without a compensatory decrease in PDE 5. These changes were associated with a decrease in tissue cGMP concentrations during treatment. These data, taken together with previous investigations on NOS activity, suggest that decreased endogenous cGMP production mediates, at least in part, the nonsustained responsiveness to NO and the rebound pulmonary hypertension associated with withdrawal of inhaled NO therapy. Therefore, PDE 5 inhibitors may be useful co-therapies to augment the vasodilatory effects of inhaled NO and facilitate its discontinuation. In fact, sildenafil, a selective PDE 5 inhibitor, has been shown in recent human studies to augment the effect of inhaled NO and facilitate its weaning. 29, 30 We speculate that a better understanding of the mechanism by which inhaled NO alters endogenous endothelial function will continue to lead to strategies that maximize the benefits of NO treatment while minimizing its toxicities, particularly during chronic therapy. In addition, these mechanisms may have important general clinical implications for a variety of both pulmonary and systemic vascular disorders, which include sickle cell disease, coronary artery disease, and nitrate tolerance. 
